Human PilotPubMed ID: 36789236·2023

Tirzepatide Improves Liver Histology in NASH

Harrison SA, Gupta A, TZP-LDL Study Group, et al.

Hepatology, 2023 · n = 283

Key finding

Tirzepatide 15mg reduced liver fat by 64%, achieved NASH resolution in 61% versus 17% placebo (p<0.001).

Summary

Phase 2b liver biopsy trial showing tirzepatide reduced NASH activity and fibrosis compared to placebo.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot